Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 4.550-4.650 for the period, compared to the consensus estimate of 4.580. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Analyst Ratings Changes

PBH has been the topic of several analyst reports. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Trading Up 3.0%

Shares of PBH traded up $1.60 during trading on Thursday, reaching $54.58. 836,300 shares of the company traded hands, compared to its average volume of 509,305. The stock has a 50-day simple moving average of $48.67 and a 200-day simple moving average of $56.07. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. Prestige Consumer Healthcare has a twelve month low of $42.62 and a twelve month high of $72.89. The stock has a market cap of $2.59 billion, a PE ratio of 13.96, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.88 by $0.10. The business had revenue of $265.71 million during the quarter, compared to analyst estimates of $250.34 million. Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The company’s quarterly revenue was up 6.5% on a year-over-year basis. During the same period last year, the business posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.45 earnings per share for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. grew its position in Prestige Consumer Healthcare by 7.5% during the fourth quarter. Invesco Ltd. now owns 584,021 shares of the company’s stock worth $36,028,000 after buying an additional 40,950 shares during the period. State of Tennessee Department of Treasury boosted its stake in shares of Prestige Consumer Healthcare by 2.8% during the 4th quarter. State of Tennessee Department of Treasury now owns 16,049 shares of the company’s stock worth $1,035,000 after acquiring an additional 435 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $2,624,000. Millennium Management LLC grew its holdings in shares of Prestige Consumer Healthcare by 72.5% in the 4th quarter. Millennium Management LLC now owns 31,099 shares of the company’s stock worth $1,918,000 after acquiring an additional 13,069 shares during the period. Finally, Man Group plc increased its stake in Prestige Consumer Healthcare by 59.3% in the 4th quarter. Man Group plc now owns 173,865 shares of the company’s stock valued at $10,726,000 after purchasing an additional 64,755 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).